Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Cancer therapy

Targeting molecular vulnerabilities in glioblastoma

Nature Medicine (2025)Cite this article

Subjects

Despite mixed efficacy outcomes, a phase 1/2 umbrella trial brings the glioblastoma field closer to a new era of diagnostic precision and targeted therapy.

Access through your institution
Buy or subscribe

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Overview of the N2M2/NOA-20 trial targeting molecular vulnerabilities in GBM.

References

  1. Louis, D. N. et al. Neuro Oncol. 23, 1231–1251 (2021).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  2. Hegi, M. E. et al. N. Engl. J. Med. 352, 997–1003 (2005).

    Article  PubMed  CAS  Google Scholar 

  3. Wick, W. et al. Nat. Med. https://doi.org/10.1038/s41591-025-03928-9 (2025).

    Article  PubMed  PubMed Central  Google Scholar 

  4. Franz, D. N. et al. Lancet Oncol. 15, 1513–1520 (2014).

    Article  PubMed  CAS  Google Scholar 

  5. Kessler, T. et al. Neurooncol. Adv. 2, vdz060 (2020).

    PubMed  PubMed Central  Google Scholar 

  6. Wick, W. et al. Neuro Oncol. 21, 95–105 (2019).

    Article  PubMed  CAS  Google Scholar 

  7. Hegi, M. E. et al. Neuro Oncol. 26, 1867–1875 (2024).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  8. Alexander, B. M. et al. Clin. Cancer Res. 24, 737–743 (2018).

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurosurgery, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

    Joshua D. Bernstock

  2. Department of Neurosurgery, Boston Children’s Hospital, Harvard Medical School, Boston, MA, USA

    Joshua D. Bernstock

  3. David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA

    Joshua D. Bernstock

Authors
  1. Joshua D. Bernstock
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Joshua D. Bernstock.

Ethics declarations

Competing interests

J.D.B. has an equity position in Treovir and UpFront Diagnostics. J.D.B. is also a cofounder of Centile Bioscience and on the NeuroX1, QV Bioelectronics and Synaptive Medical board of directors.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bernstock, J.D. Targeting molecular vulnerabilities in glioblastoma. Nat Med (2025). https://doi.org/10.1038/s41591-025-03952-9

Download citation

  • Published:

  • DOI: https://doi.org/10.1038/s41591-025-03952-9

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer